- Home
- RYM vs PRLD Comparison
RYM vs PRLD Comparison
Compare RYM & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYM
- PRLD
- Stock Information
- Founded
- RYM 2016
- PRLD 2016
- Country
- RYM United States
- PRLD United States
- Employees
- RYM 141
- PRLD N/A
- Industry
- RYM Farming/Seeds/Milling
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- RYM Consumer Staples
- PRLD Health Care
- Exchange
- RYM Nasdaq
- PRLD Nasdaq
- Market Cap
- RYM 75.6M
- PRLD 69.1M
- IPO Year
- RYM 2021
- PRLD 2020
- Fundamental
- Price
- RYM $37.75
- PRLD $1.64
- Analyst Decision
- RYM
- PRLD Strong Buy
- Analyst Count
- RYM 0
- PRLD 3
- Target Price
- RYM N/A
- PRLD $4.00
- AVG Volume (30 Days)
- RYM 21.0K
- PRLD 273.5K
- Earning Date
- RYM 11-13-2025
- PRLD 10-31-2025
- Dividend Yield
- RYM N/A
- PRLD N/A
- EPS Growth
- RYM N/A
- PRLD N/A
- EPS
- RYM N/A
- PRLD N/A
- Revenue
- RYM $12,260,000.00
- PRLD $7,000,000.00
- Revenue This Year
- RYM N/A
- PRLD N/A
- Revenue Next Year
- RYM N/A
- PRLD N/A
- P/E Ratio
- RYM N/A
- PRLD N/A
- Revenue Growth
- RYM 186.99
- PRLD N/A
- 52 Week Low
- RYM $2.94
- PRLD $0.61
- 52 Week High
- RYM $84.44
- PRLD $1.91
- Technical
- Relative Strength Index (RSI)
- RYM N/A
- PRLD 61.54
- Support Level
- RYM N/A
- PRLD $1.49
- Resistance Level
- RYM N/A
- PRLD $1.72
- Average True Range (ATR)
- RYM 0.00
- PRLD 0.16
- MACD
- RYM 0.00
- PRLD 0.03
- Stochastic Oscillator
- RYM 0.00
- PRLD 87.35
About RYM RYTHM Inc. Common Stock
Rythm Inc is a USA Based company. The Company's portfolio of brands delivers well-being to millions of Americans every year. The company features some of the recognized and trusted names in the cannabis and hemp industries, including RYTHM, incredibles, Dogwalkers, Beboe, Senorita THC Margaritas, &Shine, Doctor Solomon's and Good Green in thousands of physical locations and online channels. With products rooted in quality, safety, and innovation, the Company is shaping cannabis experiences that enhance daily life.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.